$-0.01
(Market cap
$11 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
0
P/B Ratio
3.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.1 %
-
ROCE
-- %
-
Industry P/E
37.91
-
EV/EBITDA
-0.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.3
-
Face value
--
-
Shares outstanding
45,109,497
10 Years Aggregate
CFO
$-74.28 Mln
EBITDA
$-339.64 Mln
Net Profit
$-578.48 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
GT Biopharma (GTBP)
| -69.3 | -21.9 | -45.1 | -74.4 | -69.4 | -75.1 | -69.3 |
|
BSE Sensex*
| -10.1 | -3.6 | 2.5 | -5.7 | 4.9 | 5.5 | 10.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
GT Biopharma (GTBP)
| -74.3 | -59.8 | -71.2 | -71.0 | -57.7 | 423.5 | -87.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
GT Biopharma (GTBP)
|
0.2 | 10.9 | 0.0 | -22.1 | -- | -472.1 | 0 | 3.6 |
| 17.4 | 6,074.3 | 3,117.6 | 157.4 | 14.7 | -- | 36.3 | 188.5 | |
| 206.7 | 10,826.1 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 131.0 | |
| 74.8 | 14,630.7 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 111.6 | 12,065.9 | 830.8 | 54.9 | 3.2 | 8.1 | 248 | 17.3 | |
| 12.0 | 10,020.9 | 332,834.2 | 33,166.6 | 11.1 | 8.9 | 29.3 | 2.5 | |
| 24.5 | 12,236.5 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.9 | |
| 285.6 | 5,693.6 | 290.5 | 197.2 | 82.5 | 19.9 | 29.8 | 5.9 | |
| 68.7 | 6,145.7 | 450.9 | 138.6 | 39.1 | 115.6 | 49 | 30.7 | |
| 124.7 | 8,210.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 19.0 |
Shareholding Pattern
View DetailsAbout GT Biopharma (GTBP)
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE)... platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California. Read more
-
Interim CEO & Executive Chairman
Mr. Michael Martin Breen
-
Interim CEO & Executive Chairman
Mr. Michael Martin Breen L.L.B.
-
Headquarters
San Francisco, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for GT Biopharma (GTBP)
What is the current share price of GT Biopharma Inc (GTBP) Today?
The share price of GT Biopharma Inc (GTBP) is $0.24 (NASDAQ) as of 04-Sep-2026 19:47 EDT. GT Biopharma Inc (GTBP) has given a return of -69.42% in the last 3 years.
What is the current PB & PE ratio of GT Biopharma Inc (GTBP)?
Since, TTM earnings of GT Biopharma Inc (GTBP) is negative, P/E ratio is not available.
The P/B ratio of GT Biopharma Inc (GTBP) is 3.62 times as on 04-Sep-2026, a 53 discount to its peers’ median range of 7.69 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.15 |
0.75 |
2024 |
-0.44 |
-3.46 |
2023 |
-0.05 |
0.05 |
2022 |
-0.05 |
0.09 |
2021 |
-0.45 |
1.20 |
What is the 52 Week High and Low of GT Biopharma Inc (GTBP)?
The 52-week high and low of GT Biopharma Inc (GTBP) are Rs 1.37 and Rs 0.22 as of 07-Sep-2026.
What is the market cap of GT Biopharma Inc (GTBP)?
GT Biopharma Inc (GTBP) has a market capitalisation of $ 11 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in GT Biopharma Inc (GTBP)?
Before investing in GT Biopharma Inc (GTBP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.